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A rare presentation of atypical demyelination:
tumefactive multiple sclerosis causing
Gerstmann’s syndrome
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Abstract
Background: Tumefactive demyelinating lesions are a rare manifestation of multiple sclerosis (MS). Differential
diagnosis of such space occupying lesions may not be straightforward and sometimes necessitate brain biopsy.
Impaired cognition is the second most common clinical manifestation of tumefactive MS; however complex
cognitive syndromes are unusual.
Case presentation: We report the case of a 30 year old woman who presented with Gerstmann’s syndrome. MRI
revealed a large heterogeneous contrast enhancing lesion in the left cerebral hemisphere. Intravenous corticosteroids
did not stop disease progression. A tumour or cerebral lymphoma was suspected, however brain biopsy confirmed
inflammatory demyelination. Following diagnosis of tumefactive MS treatment with natalizumab effectively suppressed
disease activity.
Conclusions: The case highlights the need for clinicians, radiologists and surgeons to appreciate the heterogeneous
presentation of tumefactive MS. Early brain biopsy facilitates rapid diagnosis and management. Treatment with
natalizumab may be useful in cases of tumefactive demyelination where additional evidence supports a diagnosis of
relapsing MS.
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Background
Gerstmann’s syndrome is a rare disorder resulting from
damage to the angular gyrus of the dominant parietal lobe
leading to dysgraphia, dyscalculia, finger agnosia and left-
right disorientation [1]. In adults this syndrome is usually
seen after stroke. In younger patients inflammation, malig-
nancy and abscesses need to be considered [2].
Case presentation
A 30 year old, right-handed woman was admitted with a
two week history of word finding difficulties. There was
subtle expressive and receptive dysphasia alongside
acalculia, agraphia, finger agnosia and left-right dis-
orientation (Additional file 1), and right-sided hom-
onymous hemianopia.
Magnetic resonance imaging (MRI) of the head demon-
strated a large heterogeneous lesion associated with focal
cystic changes in the left occipito-temporal lobes with par-
tial restriction on diffusion weighted MRI (DWI) and het-
erogeneous gadolinium enhancement (Figure 1A-G). No
spinal cord lesions were detected. Long echo time proton
MR spectroscopy (MRS) of the lesion revealed an n-acetyl
aspartate (NAA)/creatine (Cr) ratio of 1.17, a choline
(Cho)/Cr ratio of 2.64 and an inverted lactate doublet curve
(Figure 1R). Cerebrospinal fluid (CSF) analysis showed nor-
mal cell count (white cells <1, red cells <1), protein of
0.39 g/L, IgG of 21 mg/L, negative microbiology screen,
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however oligo-clonal bands predominantly in CSF com-
pared to serum.
She was treated with intravenous (IV) methylpredniso-
lone (MP), 1 g daily for three consecutive days with no
clinical effect. Two weeks later the patient developed se-
vere headache with intractable vomiting. Repeat MRI
head revealed increase in size of the previously detected
lesion and three new lesions (Figure 1H-L).
Given the diagnostic uncertainty – disease progression
despite treatment with IVMP – needle biopsy was
undertaken of the large left parietal lesion. The biopsy
(Figure 2A-H) demonstrated frequent perivascular cuffs
of T lymphocytes, macrophages and fewer B lympho-
cytes. Sheets of macrophages with foamy cytoplasm were
evident in the neural parenchyma admixed with frequent
GFAP positive reactive appearing astrocytes many of
which showed abundant cytoplasm and peripherally
placed nuclei (inlet in D). Occasional Creutzfeldt cells
(inlet in E) were also identified, which is a characteristic
albeit not specific feature of inflammatory demyelin-
ation. Visible on haematoxylin-eosin stained section and
further highlighted on luxol fast blue special stain for
myelin was the relatively sharp margin between well-
myelinated areas and regions with near complete ab-
sence of myelin. Axons, however, were well-preserved
throughout. Furthermore, immunostaining for mutant
isocitrate dehydrogenase 1 protein harbouring R132H
mutation, which is present in a large proportion of dif-
fuse gliomas [3], was negative in the whole specimen.
Hence, there was no evidence of underlying glial
neoplasm. In addition, neither T lymphocytes nor B
lymphocytes showed cytological atypia thereby provid-
ing no support for a neoplastic lymphoid proliferation.
The Ki67 proliferation index was mildly increased in
keeping with reactive proliferation of the macrophages
within the lesion.
Following histological confirmation of demyelination,
and six weeks after first presentation, treatment with
natalizumab 300 mg IV once every four weeks was
started. As part of her peri-operative care, she was also
given oral dexamethasone, initially in a dose of 4 mg bd,
tapered in steps of 1 mg bd every two weeks. The last
dose of dexamethasone was taken one week prior to her
first follow-up MRI (Figure 1M-O) four weeks after
Figure 1 Axial MRI and MR spectroscopy data acquired at 3 Tesla in a 30 year old woman with tumefactive MS. Techniques used were
fluid-attenuated inversion recovery (FLAIR; A-C, H-J, P, Q), diffusion weighted imaging (DWI; D) and apparent diffusion coefficient (ADC; E) maps,
T1 before (F, K) and after administration of gadolinium contrast (G, L, O), respectively. At presentation (A-G), FLAIR showed a large area of high
signal in the left occipito-temporal region including the angular gyrus (arrow in A) and extending to the genu of the corpus callosum (A-C), while
DWI and ADC maps showed partially restricted diffusion (D, E). Significant enhancement occurs after injection of gadolinium (G). Two weeks after
presentation (H-L) FLAIR (H-J) showed increase in size of the index lesion, and three additional lesions, two in the frontal lobes (H, I) and one in
the left occipital lobe (data not shown). All four lesions enhanced after application of gadolinium (only index lesion shown in L).
Following brain biopsy, and four weeks after the first natalizumab infusion (M-O), there is significant reduction in size of the index lesion with
evidence of post-surgical cavity and minimal residual gadolinium enhancement (O) Fourteen months after first presentation, and after 13 courses
of natalizumab, no evidence of disease activity was detected (P, Q). Long echo MR spectroscopy of the tumefactive lesion at presentation revealed
significantly reduced NAA/Cr ratio, increased Cho/Cr ratio and an inverted lactate doublet curve (arrow) (R).
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commencing natalizumab. At this time point improve-
ment in language fluency and content was recorded,
underpinned by MRI evidence of reduction in size of all
lesions, and no new lesions (Figure 1M,N). After the
fourth natalizumab infusion mini mental state examin-
ation score was 27/30 (pre-treatment score = 18) and
Addenbrooke’s cognitive examination (ACE-R) score 82/
100 (pre-treatment score = 61). The second video illustrates
the improvement of the patient’s cognitive function (Add-
itional file 2). No further relapses were observed after 16
months of clinical follow-up and 14 months after commen-
cing natalizumab treatment (MRI Figure 1O-Q). However,
two complex-partial epileptic seizures occurred six and
eight months after disease onset. After starting treatment
with lamotrigine 25 mg bd no further seizures occurred.
Conclusion
Severe cognitive impairment is unusual at presentation
of MS, and alternative causes need to be ruled out [2].
Gerstmann’s syndrome has been reported in highly ac-
tive relapsing-remitting MS in combination with other
cognitive deficits [4]. In a large series of pathologically
confirmed tumefactive MS cognitive abnormalities were
found to be frequent (43% in 168 patients) with higher
Figure 2 Brain biopsy of the tumefactive multiple sclerosis lesion. Inflammation (A-D): Haematoxylin-Eosin (H & E) stained section (A) reveals
perivascular infiltrate of mononuclear inflammatory cells (blue arrowheads). Many of the inflammatory cells are CD3 positive T cells (B) some of which
show spilling in the surrounding neural parenchyma. Fewer perivascular lymphocytes are CD20 positive B cells (C). There are also frequent
macrophages around the blood vessels and diffusely in the neural parenchyma (D). The macrophages are intermingled with glial fibrillary
acid protein (GFAP) positive stellate astrocytes (inlet in D) and Creutzfeldt cells (inlet in E, black arrowhead). Demyelination (E-H): H & E
stained section (E) shows that the margin between the lesion and the surrounding neural parenchyma is relatively sharp (indicated by
the dotted line between myelinated (My) and demyelinated (De) regions). Luxol fast blue histochemical preparation (F) confirms almost
complete loss of myelin in the lesion, while immunostaining for neurofilaments (G) shows that the axons in the same area are well-preserved.
Immunostaining for CD68 (H) further highlights the margin between demyelinated and myelinated areas and reveals numerous foamy macrophages
within the demyelinated foci. Scale bar: 100 μm (A-H); 10 μm (inlets in D and E).
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cognitive involvement (aphasia, apraxia and agnosia) in
25% of cases. However, these cases were polysymptom-
atic [5]. Isolated lesions causing a specific cognitive syn-
drome such as in our case are exceptionally rare.
In most instances of demyelination, the associated
clinical picture, MRI appearances, and CSF findings
are sufficient to make a diagnosis. Despite the presence
of oligo-clonal bands predominant in the CSF, how-
ever, the clinical deterioration and lack of treatment
response to high-dose i.v. steroids associated with an
increase in size of the tumefactive lesion and the oc-
currence of additional brain lesions prompted us to ob-
tain a brain biopsy.
DWI, which provides estimates of water diffusion in
biologic tissues, can be used in the assessment of tu-
mours. Diffusion within a neoplasm is a marker of its
cellularity as cells constitute a barrier to diffusion. As
CNS lymphomas are highly cellular tumours, diffusion is
restricted, making them appear hyper-intense on DWI and
hypo-intense on apparent diffusion coefficient (ADC) maps
[6]. However, large tumefactive lesions, such as in our case,
may be indistinguishable from neoplasms as both can lead
to mass effect/oedema, a hypo-intense rim on T2 weighted
scans, venular enhancement, peripheral restriction on
DWI, and a variable degree of ring-enhancement [7]. Clin-
ical deterioration and rapid enlargement of the tumefactive
lesion in our case, with restricted diffusion despite
IVMP treatment, confounded the diagnosis of MS and
underpinned the need for biopsy to exclude primary
CNS lymphoma.
The findings on proton MRS of an NAA/Cr ratio well
below normal may be indicative of axonal dysfunction or
loss whilst the significantly increased Cho/Cr ratio sug-
gested increased cell-membrane metabolism. However,
these findings, as well as the ‘inverted doublet’ shape of
the lactate curve may occur in tumefactive demyelinat-
ing lesions and tumours alike [8]. Thus, like DWI, MRS
did not enable a non-invasive diagnosis in our case.
The evidence regarding prognosis and disease course
of tumefactive MS remains controversial. Lesions larger
than 5cm have been reported as being associated with a
higher disability at follow-up [5], and patients who de-
velop clinically definite MS after tumefactive presenta-
tion appeared to have a more aggressive disease course
[9]. On the other hand, Wattamwar and co-workers
described a series of 14 patients who made an excellent
recovery from their large demyelinating lesions [10].
There is no standard immunomodulatory treatment
for people with tumefactive MS. Treatment choices in-
clude IVMP, β-Interferons, plasma exchange (PLEX),
rituximab and natalizumab [4,11-14]. In their recent re-
view Hardy et al. proposed an algorithm for the acute man-
agement using IVMP and/or PLEX followed by disease
modification using immunomodulatory agents [15]. The
disease course in our patient suggests excellent treatment
response to natalizumab, further supporting the diagnosis
of relapsing MS (with tumefactive lesion leading to first
presentation). Trial evidence shows natalizumab may be ef-
fective within weeks after a single infusion. In a study com-
paring two doses of natalizumab (3 mg and 6 mg/kilogram
body weight) with placebo, Miller et al. reported significant
reduction of gadolinium-enhancing lesions four weeks after
their first infusion of either dose [16]. However, despite the
initial lack of treatment response to IVMP in our case, a
subsequent corroborating effect of peri-operative dexa-
methasone on the clinical course and resolution of lesions
cannot be excluded. Of note, tumefactive lesions have also
been reported in the context of switching immunomodula-
tory therapy in people with MS as described following a
switch to fingolimod from natalizumab [17] and IFN [18],
respectively. An inhibitory effect of fingolimod on the regu-
latory T cell pool has been hypothesized as a potential
cause, though the evidence is so far inconclusive [19].
In summary, we present video, MRI and pathological
evidence of a case of tumefactive MS which posed
a diagnostic dilemma due to its atypical clinical and
radiological presentation, and lack of response to steroid
treatment. Clinicians, radiologists and surgeons need to
appreciate the heterogeneous presentation of this dis-
order, and an early brain biopsy is often necessary for
rapid diagnosis and management. Treatment with natali-
zumab may be useful in cases of tumefactive demyelin-
ation where additional evidence supports a diagnosis of
relapsing MS.
Patient consent
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Additional file 1: Video 1. Cognitive assessment of the patient before
treatment.
Additional file 2: Video 2. Cognitive assessment of the patient after
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disorientation are shown (video 1), which have subsided on subsequent
assessment (video 2).
Competing interest
KS is a PI on trials sponsored by Novartis and Roche. He has received
speaking honoraria from Merck-Serono and Novartis, served on advisory
boards for Biogen, Merck Inc, Merck-Serono, Novartis and Teva, and has
received grant support from Novartis.
Authors’ contributions
SG wrote the draft manuscript and prepared the videos. ZJ provided the
histological analysis, prepared pathology images and was involved in
drafting of the manuscript. KPB and SaG prepared MR images and were
involved in drafting the manuscript. KS initiated the study, reviewed and
edited the manuscript, and approved the final version. All authors read and
approved the final manuscript.
Gnanapavan et al. BMC Neurology 2014, 14:68 Page 4 of 5
http://www.biomedcentral.com/1471-2377/14/68
Acknowledgements
We acknowledge the expert advice by consultant neuropathologists
Professor Silvia Marino, Professor Tamas Revesz and Professor Sebastian
Brandner. KS has been supported by a Higher Education Funding Council for
England (HEFCE) Clinical Senior Lectureship.
Author details
1Blizard Institute, Barts and The London School of Medicine & Dentistry,
Queen Mary, University of London, London, UK. 2Department of Neurology,
Barts Health NHS Trust, The Royal London Hospital, London, UK. 3Division of
Neuropathology, UCLH Foundation Trust, The National Hospital for
Neurology & Neurosurgery, Queen Square, London, UK. 4Department of
Neuroradiology, Barts Health NHS Trust, The Royal London Hospital, London, UK.
Received: 10 October 2013 Accepted: 17 March 2014
Published: 2 April 2014
References
1. Clark C, Howard R, Rosser M, Shorvon S: Neurology: A Queen Square
Textbook. 1st edition. UK: Wiley-Blackwell; 2009.
2. Wallner-Blazek M, Rovira A, Fillipp M, Rocca MA, Miller DH, Schmierer K,
Frederiksen J, Gass A, Gama H, Tilbery CP, Rocha AJ, Flores J, Barkhof F,
Seewann A, Palace J, Yousry T, Montalban X, Enzinger C, Fazekas F: Atypical
idiopathic inflammatory demyelinating lesions: prognostic implications
and relation to multiple sclerosis. J Neurol 2013, 260(8):2016–2022.
3. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J,
Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A,
Jeuken JW, Wesseling P, Reifenberger G, von Deimling A: Type and frequency
of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial
differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol
2009, 118(4):469–474.
4. Ehrle N, Maarouf A, Chaunu MP, Sabbagh-Peignot S, Bakchine S: Acquired
and developmental Gerstmann syndrome. Illustration from a patient
with multiple sclerosis. Revue neurologique 2012, 168(11):852–860.
5. Lucchinetti CF, Gavrilova RH, Metz I, Parisi JE, Scheithauer BW, Weigand S,
Thomsen K, Mandrekar J, Altintas A, Erickson BJ, König F, Giannini C,
Lassmann H, Linbo L, Pittock SJ, Brück W: Clinical and radiographic
spectrum of pathologically confirmed tumefactive multiple sclerosis.
Brain 2008, 131(Pt 7):1759–1775.
6. Haldorsen IS, Espeland A, Larsson EM: Central nervous system lymphoma:
characteristic findings on traditional and advanced imaging. AJNR Am J
Neuroradiol 2011, 32(6):984–992.
7. Kiriyama T, Kataoka H, Taoka T, Tonomura Y, Terashima M, Morikawa M,
Tanizawa E, Kawahara M, Furiya Y, Sugie K, Kichikawa K, Ueno S:
Characteristic neuroimaging in patients with tumefactive demyelinating
lesions exceeding 30 mm. J Neuroimaging 2011, 21(2):e69–e77.
8. Saindane AM, Cha S, Law M, Xue X, Knopp EA, Zagzag D: Proton MR
spectroscopy of tumefactive demyelinating lesions. AJNR Am J
Neuroradiol 2002, 23(8):1378–1386.
9. Selkirk SM, Shi J: Relapsing-remitting tumefactive multiple sclerosis.
Mult Scler 2005, 11(6):731–734.
10. Wattamwar PR, Baheti NN, Kesavadas C, Nair M, Radhakrishnan A: Evolution
and long term outcome in patients presenting with large demyelinating
lesions as their first clinical event. J Neurol Sci 2010, 297(1–2):29–35.
11. Seifert CL, Wegner C, Sprenger T, Weber MS, Bruck W, Hemmer B, Sellner J:
Favourable response to plasma exchange in tumefactive CNS demyelination
with delayed B-cell response. Mult Scler 2012, 18(7):1045–1049.
12. Launay M, Lebrun C, Giordana E, Chanalet S, Thomas P: Clinical, radiographic,
prognostic and therapeutic aspects of demelinating disease with tumefactive
demyelinating lesions. Rev Neurol 2011, 167(1):14–22.
13. Kalanie H, Harandi AA, Bakhshandehpour R, Heidari D: Multiple Large
Tumefactive MS Plaques in a Young Man: A Diagnostic Enigma and
Therapeutic Challenge. Case reports in radiology 2012, 2012:363705.
14. Fan X, Mahta A, De Jager PL, Kesari S: Rituximab for tumefactive
inflammatory demyelination: a case report. Clin Neurol Neurosurg 2012,
114(10):1326–1328.
15. Hardy TA, Chataway J: Tumefactive demyelination: an approach to diagnosis
and management. J Neurol Neurosurg Psychiatry 2013, 84(9):1047–1053.
16. Miller DH, Khan OA, Sheremata WA, Blumhardt LD, Rice GP, Libonati MA,
Willmer-Hulme AJ, Dalton CM, Miszkiel KA, O'Connor PW: A controlled trial
of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003,
348(1):15–23.
17. Jander S, Turowski B, Kieseier BC, Hartung HP: Emerging tumefactive
multiple sclerosis after switching therapy from natalizumab to
fingolimod. Mult Scler 2012, 18(11):1650–1652.
18. Castrop F, Kowarik MC, Albrecht H, Krause M, Haslinger B, Zimmer C,
Berthele A, Hemmer B: Severe multiple sclerosis relapse under fingolimod
therapy: incident or coincidence? Neurology 2012, 78(12):928–930.
19. Meluzinova E, Bojar M, Havrdova E, Liskova P, Kappos L: Severe multiple sclerosis
relapse under fingolimod therapy. Mult Scler 2012, 18(4 suppl):459.
doi:10.1186/1471-2377-14-68
Cite this article as: Gnanapavan et al.: A rare presentation of atypical
demyelination: tumefactive multiple sclerosis causing Gerstmann’s
syndrome. BMC Neurology 2014 14:68.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Gnanapavan et al. BMC Neurology 2014, 14:68 Page 5 of 5
http://www.biomedcentral.com/1471-2377/14/68
